YTHDF2-mediated mA modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI.
[AIMS] Chemoresistance results in poor outcomes of patients with gastric cancer (GC).
APA
Fan X, Han F, et al. (2025). YTHDF2-mediated mA modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI.. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 79, 101200. https://doi.org/10.1016/j.drup.2024.101200
MLA
Fan X, et al.. "YTHDF2-mediated mA modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI.." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, vol. 79, 2025, pp. 101200.
PMID
39823826
Abstract
[AIMS] Chemoresistance results in poor outcomes of patients with gastric cancer (GC). This study aims to identify oxaliplatin resistance-related cell subpopulations in the tumor microenvironment (TME) and decipher the involved molecular mechanisms.
[METHODS] Through single-cell RNA sequencing, a unique ONECUT2TFPI GC cell subset was identified in the oxaliplatin-resistant TME. The functional roles and molecular mechanisms of ONECUT2 in oxaliplatin resistance were investigated in cellular and mouse models. Therapeutic efficacy of small molecule inhibitor of ONECUT2 was also evaluated.
[RESULTS] The abundance of ONECUT2TFPI GC cell subset was elevated in oxaliplatin-resistant GC tumors. ONECUT2 was up-regulated and associated with undesirable prognostic outcomes of patients with GC. ONECUT2 facilitated GC cell migration, stemness properties and oxaliplatin resistance. YTHDF2, an mA "reader", was down-regulated in GC, and its overexpression facilitated ONECUT2 mRNA degradation through mA modification. Furthermore, ONECUT2 transcriptionally activated TFPI through binding to its promoter. Small molecule inhibitor CSRM617 targeting ONECUT2 was well tolerated in GC mouse models, and could effectively improve therapeutic efficacy of oxaliplatin against GC.
[CONCLUSIONS] Our study demonstrates that YTHDF2-mediated mA modification of ONECUT2 results in stemness and oxaliplatin resistance in GC through transcriptionally activating TFPI, which provides a novel therapeutic target against oxaliplatin-resistant GC.
[METHODS] Through single-cell RNA sequencing, a unique ONECUT2TFPI GC cell subset was identified in the oxaliplatin-resistant TME. The functional roles and molecular mechanisms of ONECUT2 in oxaliplatin resistance were investigated in cellular and mouse models. Therapeutic efficacy of small molecule inhibitor of ONECUT2 was also evaluated.
[RESULTS] The abundance of ONECUT2TFPI GC cell subset was elevated in oxaliplatin-resistant GC tumors. ONECUT2 was up-regulated and associated with undesirable prognostic outcomes of patients with GC. ONECUT2 facilitated GC cell migration, stemness properties and oxaliplatin resistance. YTHDF2, an mA "reader", was down-regulated in GC, and its overexpression facilitated ONECUT2 mRNA degradation through mA modification. Furthermore, ONECUT2 transcriptionally activated TFPI through binding to its promoter. Small molecule inhibitor CSRM617 targeting ONECUT2 was well tolerated in GC mouse models, and could effectively improve therapeutic efficacy of oxaliplatin against GC.
[CONCLUSIONS] Our study demonstrates that YTHDF2-mediated mA modification of ONECUT2 results in stemness and oxaliplatin resistance in GC through transcriptionally activating TFPI, which provides a novel therapeutic target against oxaliplatin-resistant GC.
MeSH Terms
Stomach Neoplasms; Oxaliplatin; Humans; Drug Resistance, Neoplasm; Animals; Mice; RNA-Binding Proteins; Tumor Microenvironment; Cell Line, Tumor; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Cell Movement; Lipoproteins; Xenograft Model Antitumor Assays; Neoplastic Stem Cells; Adenosine
같은 제1저자의 인용 많은 논문 (5)
- Polo-like kinase 5 is lowly expressed and negatively correlates with poorer differentiation, and its positivity may predict a better prognosis in patients with colorectal cancer.
- Mechanisms of angiopoietin-like protein 7 regulation and therapeutic potential in tumors.
- Robustness and Accuracy of Radiomics Models for Classifying IASLC Grading in Lung Adenocarcinomas: A Comprehensive Analysis of a Large Multicenter CT Database.
- CRISPR-Cas9-Loaded Theranostic Liposomes for Enhancing Radiosensitization of Prostate Cancer through POLD4 Gene Editing under Real-Time MRI Monitoring.
- 3D deep learning model to predict the recurrence of stage IA invasive lung adenocarcinoma after sub-lobar resection: a multicenter retrospective cohort study.